ArticleDiabetes, obesity & metabolism2025
The healthcare and economic burden associated with inadequate risk factor control for type 2 diabetes in Hong Kong: A population-based modelling study.
Article in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The healthcare and economic burden associated with inadequate risk factor control for type 2 diabetes in Hong Kong: A population-based modelling study.Diabetes, obesity & metabolism · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimTo estimate the healthcare and economic burden associated with improved risk factor control for people with type 2 diabetes in Hong Kong over 10 years. MATERIALS AND
methodsWe obtained population-based data from electronic healthcare records of the Hong Kong Hospital Authority. Risk factor targets were defined by American Diabetes Association guidelines. We applied a validated patient-level diabetes outcomes model (Chinese Hong Kong Integrated Modelling and Evaluation) to estimate the health and economic outcomes for all individuals with type 2 diabetes (n = 526 672) in Hong Kong in 2021. Immediate risk factor control was compared to baseline over 10 years. Costs were estimated from a healthcare provider perspective.
resultsMost people (84.9%) failed to achieve optimal combined risk factors control (glycated haemoglobin, blood pressure and low-density lipoprotein-cholesterol) at baseline. Combined control was associated with population-level increases in quality-adjusted life-years (QALYs) of 17 605 and healthcare cost savings of US$ 106.7 million over 10 years. Glycaemic control solely yielded the greatest QALY increases and had the highest cost savings (US$ 29.0 million) over 10 years.
conclusionsThe substantial population health and economic burden of inadequate risk factor control for individuals with diabetes in Hong Kong can potentially be mitigated through enhanced adherence, highlighting the need for effective and intensive interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.